NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High-Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)
NeOnc Technologies Holdings, Inc. (NTHI)
Company Research
Source: GlobeNewswire
CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial. The trial is evaluating the company’s lead therapeutic candidate, NEO100, for the treatment of recurrent isocitrate dehydrogenase 1 (IDH1)–mutant high-grade glioma (WHO Grade III and IV). The Company anticipates reporting preliminary data from this fully enrolled cohort in approximately six months, during the second quarter of 2026. “Completing enrollment for our Phase 2a trial marks a defining inflection point for NeOnc Technologies,” said Amir Heshmatpour, Executive Chairman, President & CEO. “This achievement follows exceptionally positive interim data and propels us into the next stage of value creation for NEO100 a novel, intr
Show less
Read more
Impact Snapshot
Event Time:
NTHI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTHI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTHI alerts
High impacting NeOnc Technologies Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
NTHI
News
- NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors [Yahoo! Finance]Yahoo! Finance
- NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain TumorsGlobeNewswire
- With 61% ownership, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) insiders have a lot riding on the company's future [Yahoo! Finance]Yahoo! Finance
- NeOnc Technologies Holdings GAAP EPS of -$0.45 [Seeking Alpha]Seeking Alpha
- NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational UpdateGlobeNewswire
NTHI
Sec Filings
- 12/5/25 - Form 8-K
- 11/24/25 - Form 4
- 11/24/25 - Form 3
- NTHI's page on the SEC website